51
Participants
Start Date
April 7, 2022
Primary Completion Date
April 13, 2023
Study Completion Date
April 13, 2023
ADX-629
Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
Placebo
Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
Mount Sinai, New York
Charlotte Lung & Health/American Health Research, Charlotte
Clinical Research of Rock Hill, Rock Hill
ClinCept, Columbus
Florida Pulmonary Research Institute LLC, Winter Park
Cano Research - Hollywood, Hollywood
Advanced Pulmonary Research Institute, Loxahatchee Groves
Bernstein Clinical Research Center, LLC, Cincinnati
Mayo Clinic Pulmonary Clinic Research Unit, Rochester
Pharmaceutical Research and Consulting Inc., Dallas
Vital Prospects Clinical Research, Tulsa
Allergy Associates Medical Group, Inc., San Diego
Allergy & Asthma Associates of Santa Clara Valley Research Center, San Jose
Northwest Research Center, Portland
Lead Sponsor
Aldeyra Therapeutics, Inc.
INDUSTRY